Intranasal carbetocin dose 1    (DrugBank: Carbetocin)

1 disease
IDDisease name (Link within this page)Number of trials
193Prader-Willi syndrome1

193. Prader-Willi syndrome    [ 95 clinical trials,   104 drugs,   (DrugBank: 27 drugs),   50 drug target genes,   63 drug target pathways]
Searched query = "Prader-Willi syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 95 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03649477
(ClinicalTrials.gov)
November 20, 201824/8/2018Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi SyndromePhase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)Prader-Willi SyndromeDrug: intranasal carbetocin Dose 1;Drug: intranasal carbetocin Dose 2;Drug: placeboLevo Therapeutics, Inc.NULLActive, not recruiting7 Years18 YearsAll130Phase 3United States;Australia;Canada